Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sanofi Could Pursue Other Oncology M&A Targets After Medivation Loss

Aug 24 2016

• By Joseph Haas

Related Content

Incyte's Oncology Strategy: Putting Its Eggs In Many Mechanistic Baskets

May 16 2016

Medivation Rejects Sanofi's Latest Bid, But Enters Confidential Negotiations

Jul 06 2016

Pfizer’s $14bn Medivation Buyout Shows How Far Pharma Will Go In Oncology

Aug 22 2016

Pfizer's Medivation Buyout: One-Off Deal Or Start Of A Biopharma Spending Spree?

Aug 23 2016

Incyte Tumbles On More Jakafi Trial Terminations

Feb 12 2016

Sanofi Earnings Emphasize Need For Medivation Buy

Apr 30 2016

Sanofi plays catch-up in immuno-oncology with new Regeneron deal

Jul 28 2015

Related Companies

Sanofi

Pfizer Inc.

Vertex Pharmaceuticals Incorporated

Biogen, Inc.

BioMarin Pharmaceutical Inc.

Regeneron Pharmaceuticals, Inc.

Incyte Corporation

ARIAD Pharmaceuticals, Inc.

Sanofi Genzyme

Takeda Pharmaceutical Co. Ltd.

Novartis AG

Additional Topics

France Europe Commercial Deals M & A Cancer BioPharmaceutical

More from Business

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window